BRPI0809081A2 - compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6 - Google Patents
compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6Info
- Publication number
- BRPI0809081A2 BRPI0809081A2 BRPI0809081A BRPI0809081A BRPI0809081A2 BR PI0809081 A2 BRPI0809081 A2 BR PI0809081A2 BR PI0809081 A BRPI0809081 A BR PI0809081A BR PI0809081 A BRPI0809081 A BR PI0809081A BR PI0809081 A2 BRPI0809081 A2 BR PI0809081A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds suitable
- serotonin receptor
- treating disorders
- receptor modulation
- quinoline compounds
- Prior art date
Links
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104806 | 2007-03-23 | ||
| PCT/EP2008/053387 WO2008116831A1 (en) | 2007-03-23 | 2008-03-20 | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0809081A2 true BRPI0809081A2 (pt) | 2019-09-24 |
Family
ID=39620293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809081A BRPI0809081A2 (pt) | 2007-03-23 | 2008-03-20 | compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8242102B2 (enExample) |
| EP (1) | EP2139880B1 (enExample) |
| JP (1) | JP5538907B2 (enExample) |
| KR (1) | KR20090128426A (enExample) |
| CN (1) | CN101679351B (enExample) |
| AR (1) | AR068381A1 (enExample) |
| AT (1) | ATE524456T1 (enExample) |
| AU (1) | AU2008231787A1 (enExample) |
| BR (1) | BRPI0809081A2 (enExample) |
| CA (1) | CA2681030C (enExample) |
| CO (1) | CO6230989A2 (enExample) |
| CR (1) | CR11039A (enExample) |
| DO (1) | DOP2009000228A (enExample) |
| EC (1) | ECSP099651A (enExample) |
| ES (1) | ES2373617T3 (enExample) |
| IL (1) | IL201105A0 (enExample) |
| MX (1) | MX2009010243A (enExample) |
| NZ (1) | NZ579735A (enExample) |
| PE (1) | PE20091187A1 (enExample) |
| RU (1) | RU2009139073A (enExample) |
| TW (1) | TW200940524A (enExample) |
| UA (1) | UA97837C2 (enExample) |
| UY (1) | UY31326A (enExample) |
| WO (1) | WO2008116831A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| US20130343993A1 (en) * | 2012-01-06 | 2013-12-26 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| CN109503449A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1219618A4 (en) * | 1999-09-02 | 2002-09-18 | Wakunaga Pharma Co Ltd | QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT |
| JP2003277416A (ja) | 2002-03-22 | 2003-10-02 | Daiyanitorikkusu Kk | 糖類を含むアクリルアミド水溶液 |
| ATE398108T1 (de) * | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| US20050165006A1 (en) | 2002-04-03 | 2005-07-28 | Dae-Yoon Chi | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
| PL374401A1 (en) | 2002-06-05 | 2005-10-17 | F.Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
| GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| CA2616473A1 (en) | 2005-07-27 | 2007-03-08 | F. Hoffmann-La Roche Ag | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| ES2389958T3 (es) | 2007-03-21 | 2012-11-05 | Glaxo Group Limited | Uso de derivados de quinolina en el tratamiento del dolor |
-
2008
- 2008-03-20 NZ NZ579735A patent/NZ579735A/en not_active IP Right Cessation
- 2008-03-20 BR BRPI0809081A patent/BRPI0809081A2/pt not_active IP Right Cessation
- 2008-03-20 JP JP2009554034A patent/JP5538907B2/ja not_active Expired - Fee Related
- 2008-03-20 CN CN200880017192.XA patent/CN101679351B/zh not_active Expired - Fee Related
- 2008-03-20 KR KR1020097019918A patent/KR20090128426A/ko not_active Withdrawn
- 2008-03-20 AU AU2008231787A patent/AU2008231787A1/en not_active Abandoned
- 2008-03-20 RU RU2009139073/04A patent/RU2009139073A/ru not_active Application Discontinuation
- 2008-03-20 ES ES08735447T patent/ES2373617T3/es active Active
- 2008-03-20 EP EP08735447A patent/EP2139880B1/en active Active
- 2008-03-20 AT AT08735447T patent/ATE524456T1/de not_active IP Right Cessation
- 2008-03-20 MX MX2009010243A patent/MX2009010243A/es active IP Right Grant
- 2008-03-20 WO PCT/EP2008/053387 patent/WO2008116831A1/en not_active Ceased
- 2008-03-20 CA CA2681030A patent/CA2681030C/en not_active Expired - Fee Related
- 2008-03-20 UA UAA200910698A patent/UA97837C2/ru unknown
- 2008-03-23 US US12/532,407 patent/US8242102B2/en not_active Expired - Fee Related
- 2008-09-02 TW TW097133636A patent/TW200940524A/zh unknown
- 2008-09-08 AR ARP080103894A patent/AR068381A1/es not_active Application Discontinuation
- 2008-09-08 PE PE2008001568A patent/PE20091187A1/es not_active Application Discontinuation
- 2008-09-08 UY UY0001031326A patent/UY31326A/es not_active Application Discontinuation
-
2009
- 2009-09-22 CO CO09103181A patent/CO6230989A2/es not_active Application Discontinuation
- 2009-09-22 IL IL201105A patent/IL201105A0/en unknown
- 2009-09-22 DO DO2009000228A patent/DOP2009000228A/es unknown
- 2009-09-23 CR CR11039A patent/CR11039A/es unknown
- 2009-09-23 EC EC2009009651A patent/ECSP099651A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL201105A0 (en) | 2010-05-17 |
| ECSP099651A (es) | 2009-10-30 |
| EP2139880A1 (en) | 2010-01-06 |
| KR20090128426A (ko) | 2009-12-15 |
| JP2010521520A (ja) | 2010-06-24 |
| UY31326A (es) | 2009-11-10 |
| CN101679351B (zh) | 2015-01-07 |
| CO6230989A2 (es) | 2010-12-20 |
| CA2681030A1 (en) | 2008-10-02 |
| PE20091187A1 (es) | 2009-09-06 |
| US8242102B2 (en) | 2012-08-14 |
| UA97837C2 (ru) | 2012-03-26 |
| DOP2009000228A (es) | 2009-10-15 |
| MX2009010243A (es) | 2009-12-14 |
| WO2008116831A1 (en) | 2008-10-02 |
| CA2681030C (en) | 2015-01-13 |
| AR068381A1 (es) | 2009-11-11 |
| ES2373617T3 (es) | 2012-02-07 |
| CN101679351A (zh) | 2010-03-24 |
| EP2139880B1 (en) | 2011-09-14 |
| CR11039A (es) | 2010-02-09 |
| TW200940524A (en) | 2009-10-01 |
| JP5538907B2 (ja) | 2014-07-02 |
| HK1139933A1 (en) | 2010-09-30 |
| ATE524456T1 (de) | 2011-09-15 |
| RU2009139073A (ru) | 2011-04-27 |
| US20110009380A1 (en) | 2011-01-13 |
| NZ579735A (en) | 2012-02-24 |
| AU2008231787A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0812853A2 (pt) | Compostos de quinolina adequados para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina. | |
| BRPI0922953A2 (pt) | aparelho redutor de haste para cirurgias de correção da coluna | |
| BR112012006630A2 (pt) | derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) | |
| BRPI1011875A2 (pt) | compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina | |
| BRPI0910274A2 (pt) | corantes marcadores para produtos de petróleo | |
| HUE036506T2 (hu) | 5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére | |
| BRPI0812755A2 (pt) | Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas | |
| BRPI0919468A2 (pt) | dispositivos de alinhamento unitário de múltiplos usos para produção de sapato | |
| BRPI0908715A2 (pt) | métodos para tratamento da psoríase | |
| BRPI0809081A2 (pt) | compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6 | |
| BRPI0812040A2 (pt) | Indicações para terapia de anti-il-i-beta | |
| BRPI0821970A2 (pt) | Análogos de pterina para tratamento de condição responsiva a bh4 | |
| BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
| BRPI0909628A2 (pt) | compostos de azaindol para o tratamento de distúrbios do sistema nervosos central | |
| BRPI1013777A2 (pt) | compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| IL201107A0 (en) | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| BRPI0808791A2 (pt) | derivados tricíclicos de isoquinolina para tratamento de obesidade | |
| BRPI0812860A2 (pt) | Rosa contendo flavona, e método para produção da mesma | |
| BRPI0914393A2 (pt) | "método para caracterização de fitoquímicos" | |
| BRPI0813832A2 (pt) | Métodos para tratamento da ansiedade | |
| BRPI0819233A2 (pt) | compostos de benzenossulfonanilida adequadas para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina | |
| BRPI0816142A2 (pt) | Modulador de nrg1 para tratamento de distúrbios respiratórios. | |
| BRPI0818726A2 (pt) | Compostos de 1,2,4-triazin-3,5-diona para tratar desordens que respondem à modulação do receptor d3 de dopamina. | |
| BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares | |
| EP2055939A4 (en) | APPARATUS FOR ERROR IDENTIFICATION IN LIGHT PENS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |